natgillin/translations-raw huggingface dataset:
Macugen bør ikke anvendes til børn og unge under 18 år.
Macugen should not be used in children and adolescents under 18 years old.
Macugen er en opløsning, der sprøjtes ind i øjet.
Macugen is a solution which is injected into the eye.
Macugen gives som én enkelt injektion (0,3 mg) i øjet med et interval på 6 uger (dvs.
Macugen is administered as a single injection (0.3 mg) into your eye at intervals of 6 weeks (i.e.
Macugen indeholder natrium
Important information about some of the ingredients of Macugen
Macugen opløsning til indsprøjtning leveres i en enkeltdosis pakning.
Macugen solution for injection is supplied in a single dose pack.
Macugen påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner på grund af potentielt forbigående sløret syn efter intravitreal injektion.
Macugen has a minor influence on the ability to drive and use machines due to the possible temporary visual blurring after administration of Macugen by intravitreal injection.
Macugens sikkerhed og virkning hos børn under 18 år er ikke klarlagt.
The safety and efficacy of Macugen in children under 18 years has not yet been established.
Maculahul
Macular hole
Maculaødem
macular oedema
Maculaødem (opsvulmen af den midterste del af nethinden).
Macular oedema (swelling of the centre of the retina).
Maculaødem, indsunkne øjne
macular oedema, sunken eyes
Maculopapulært udslæt
Maculopapular rash
Mad dit barn jævnligt for at undgå længerevarende faste.
Feed your child regularly to avoid prolonged fast.
Mad havde ringe eller ingen virkning på eksponeringen af konjugeret østrogen.
Food had little or no effect on the exposure of CE.
Mad og drikke forventes ikke at påvirke Qutenza, da det virker lokalt på din hud.
Food or drink are not expected to influence Qutenza as it acts locally on your skin.
Mad og drikke påvirker ikke MIRCERA.
Food and drink do not affect MIRCERA.
Mad og drikkevarer har ingen indflydelse på Dynepo.
Food and drink has no influence on Dynepo.
Mad påvirker ikke absorptionsomfang og -hastighed for vildagliptin fra Icandra.
Food does not affect the extent and rate of absorption of vildagliptin from Icandra.
Mad påvirker ikke biotilgængeligheden af dabigatranetexilat, men forsinker tiden til maksimum- koncentration i plasma med 2 timer.
Food does not affect the bioavailability of dabigatran etexilate but delays the time to peak plasma concentrations by 2 hours.
Mad reducerede også Cmax for den aktive metabolit, 3-hydroxyanagrelid, med 29 %, selvom det ikke havde nogen virkning på AUC.
Food also decreased the Cmax of the active metabolite, 3-hydroxy-anagrelide, by 29%, although it had no effect on the AUC.
mad tilbageholdes i maven efter måltider
Retained food in stomach after meals
mad tilbageholdes i maven efter måltider
Retained food in stomach after meals;
Mad, der indeholder grapefrugt eller bitre appelsiner bør undgås under behandlingen med Kalydeco, da den kan påvirke lægemidlets optagelse og nedbrydning i kroppen.
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco as they may affect the way the medicine is absorbed and broken down in the body.
Mad, der indeholder grapefrugt eller Sevilla-appelsiner bør undgås under behandling med Kalydeco (se pkt.
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco (see section 4.5).
Mad, der indeholder grapefrugt eller Sevilla-appelsiner, bør undgås under behandling med Kalydeco (se pkt.
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco (see section 4.5).
Mad, der indeholder grapefrugt eller Sevilla-appelsiner, bør undgås under behandling med Kalydeco.
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco.
Mad, drikkevarer og motion
Food, drink and exercise
Maden eller væsken skal have stuetemperatur eller være kold.
Food or liquid should be at room temperature or below.
Maden skal indtages med det samme og skal spises op.
The food should be immediately and completely consumed.
Madlede
Food aversion
madlede (appetitløshed)
anorexia (loss of appetite);
Madrid Spain
Spain
Madrid Spanien
Madrid Spain
Madrid Spanien
Spain
mag indeholder: maltodextrin og dextrin, naturlig smag indeholder: maltodextrin, glycerol (E422) og propylenglycol (E1520), citronsmag indeholder: maltodextrin og alfa-tokoferol (E307).
flavouring containing: maltodextrin and dextrin, natural flavouring containing: maltodextrin, glycerol (E422) and propylene glycol (E1520), lemon flavouring containing: maltodextrin and alpha-tocopherol (E307)).
Mag toegediend worden met of zonder voedsel.
It may be given with or without food.
magnesium nedsætter raltegravirs plasmakoncentration.
Aluminium and magnesium containing antacids reduce raltegravir plasma levels.
Magnesium/aluminium- indeholdende antacidum- suspension (20 ml enkeltdosis)/Elvitegravir (50 mg enkeltdosis)/Ritonavir (100 mg enkeltdosis)
Magnesium/aluminium-containing antacid suspension (20 mL single dose)/Elvitegravir (50 mg single dose)/Ritonavir (100 mg single dose)
Magnesium/aluminum-
Magnesium/aluminum-containing
Magnesiumcarbonat, tungt Macrogol 300
Silica, colloidal anhydrous Magnesium carbonate, heavy Macrogol 300
Magnesiumchlorid (MgCl2) Vand til injektionsvæsker
Magnesium chloride (MgCl2) Water for injections
Magnesiumchloridhexahydrat og vand til injektioner.
magnesium chloride hexahydrate and water for injections.
Magnesiumchloridhexahydrat Vand til injektioner
Magnesium chloride hexahydrate Water for injections
magnesiumhydroxid)
antagonists.
magnesiumhydroxid-simeticon
hydrochloride/Efavirenz
magnesiumhydroxid-simeticon
hydroxide-simethicone
magnesiumhydroxid;
magnesium
Magnesiumstearat
Colloidal anhydrous silica, Magnesium stearate.
Magnesiumstearat (E 470b) Lactosemonohydrat
Lactose monohydrate
Magnesiumstearat (E 470b) Lactosemonohydrat
Silica colloidal anhydrous Magnesium stearate (E470b) Lactose monohydrate
Magnesiumstearat (E470 B) Gul jernoxid (E172)
Magnesium stearate (E 470 B) Yellow iron oxide (E172)
Magnesiumstearat (E470b) Fycompa 6 mg, 8 mg, 10 mg, 12 mg filmovertrukne tabletter
Magnesium stearate (E470b) Fycompa 6 mg, 8 mg, 10 mg, 12 mg film-coated tablets
Magnesiumstearat (E470b) Kaliumhydroxid Meglumin
Magnesium stearate (E470b) Potassium hydroxide Meglumine
Magnesiumstearat (E470b) Natriumstivelsesglycolat Hydroxypropylcellulose (E463)
Dibasic calcium phosphate Magnesium stearate (E470b) Sodium starch glycolate Hydroxypropyl-cellulose (E463)
Magnesiumstearat (E470b) Silica, dental type (E551)
Magnesium stearate (E470b) Dental type silica (E551)
Magnesiumstearat (E572) Polysorbat 80 (E433)
Magnesium stearate (E572) Polysorbate 80 (E433)
Magnesiumstearat Filmovertræk
Film coating Hypromellose
Magnesiumstearat Jernoxid, gul (E172)
Magnesium stearate Yellow iron oxide (E172)
Magnesiumstearat Meglumin Poloxamer 188
Magnesium stearate Meglumine Poloxamer 188
Magnesiumstearat Rød jernoxid (E172)
Red iron oxide (E172)
Magnesiumstearat Rød og gul jernoxid
Red and yellow ferric oxides
Magnesiumstearat Tabletovertræk
Magnesium stearate Tablet coat
Magnesiumstearat,
Magnesium stearate
Magnesiumstearat.
Sodium laurylsulfate Magnesium stearate
Magnesiumtrisilicat (sepiolit) Hvedefodermel Hydroxypropylcellulose Fedtfrit sojapulver
Magnesium trisilicate (sepiolite) Wheat feed flour Hydroxypropyl cellulose
Magnesiumtrisilicat (sepiolite) Hvedefodermel Hydroxypropylcellulose Fedtfrit sojapulver
Magnesium trisilicate (sepiolite) Wheat feed flour Hydroxypropyl cellulose
Magnesiumtrisilicat, hvedefodermel
Magnesium trisilicate, wheat feed flour.
magsfor-
and diaphyseal
magsforandring, øget indhold af lipase og amylase (fordøjelsesenzymer) i blodet (kræver ikke behandling og normaliseres sædvanligvis efter, at behandling med Kepivance er ophørt).
altered taste; increase in lipase and amylase levels (digestive enzymes) in the blood (which do not require treatment and usually return to normal after stopping treatment with Kepivance).
magsforandringer
change in taste;
magsforandringer
changes in taste
magsforandringer, diarré, maveonde, mundsmerter,
changes in taste, diarrhoea, stomach upset, oral pain,
magsforstyrelser
taste disturbance
magsforstyrrelse kvalme
taste disturbance nausea (feeling sick)
magsforstyrrelser
alteration in sense of taste
magsforstyrrelser
altered taste
magsforstyrrelser
difficulty tasting (dysgeusia)
magsforstyrrelser
disturbed sense of taste
magsforstyrrelser
taste abnormalities
magsforstyrrelser
taste disorders
magsforstyrrelser
taste disturbance,
magsforstyrrelser
taste disturbances
magsforstyrrelser
Taste disturbances.
magsforstyrrelser
trembling
magsforstyrrelser eller ingen smagssans
taste disturbance or loss of taste
magsforstyrrelser nysen
taste disturbances sneezing
magsforstyrrelser,
change in the sense of taste,
magsforstyrrelser,
taste disturbances,
magsforstyrrelser, f.eks. at ting smager anderledes, end de plejer
taste problems – such as changes in the way things taste
magsforstyrrelser, fx at ting smager anderledes, end de plejer
taste problems – such as changes in the way things taste
magsændringer
changes in taste
magsændringer svimmelhed
changes in taste dizziness
Magyarország
Eesti
Magyarország
España
Magyarország
Magyarország CSL Behring Kft.
Magyarország (Ungarn)
Magyarország (Hungary)
Magyarország Alcon Hungária
Nederland
Magyarország GlaxoSmithKline Kft.
Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v.
Magyarország Orion Pharma Kft, 1139 Budapest, Pap Károly u.
Dechra Veterinary Products/Albrecht GmbH Veterinär-medizinische Erzeugnisse Hauptstr.
Magyarország Takeda Pharma Kft.
Magyarország Lilly Hungária Kft.
MAH erkender, at Rostoker og Cohen anbefaler mindst 6 måneder mellem administration af ferumoxytol og MR, hvilket de baserer på studiet af 6 raske frivillige publiceret af Storey et al.
However, the MAH acknowledges that Rostoker and Cohen recommend a minimum of 6 months between ferumoxytol’s administration, which they base on the study with 6 healthy volunteers published by Storey et al.
MAH forpligter sig til at fremsende data fra sit interne graviditetsregister som beskrevet i RMP.
The MAH commits to submit the data from pregnancy registry as described in the RMP.
MAH forpligter sig til at opdatere protokollen for observationsundersøgelsen til at screene for autoantistoffer hos de patienter, som oplever visuelle eller okulære hændelser i løbet af undersøgelsesopfølgningen.
The MAH commits to update the observational study protocol to screen for auto-antibodies those patients presenting visual or ocular events during the study follow- up.
MAH forpligter sig til at præsentere en plan til definition af kilderne til indsamling af sikkerhedsdata for immunkompromitterede patienter som del af den prospektive kohortesikkerhedsundersøgelse.
The MAH commits to present a plan for the definition of the sources to collect safety data on immunocompromised patient within the prospective cohort safety study.
MAH har forpligtet sig til at oprette et system til frivillig indberetning af bivirkninger som beskrevet i risikostyringsplanen.
The MAH has committed to set up a voluntary adverse event reporting system as detailed in the risk management plan.
MAH pålægges at levere opdateringer om rekrutteringshastighed og eventuelle mellemresultater årligt sammen med den årlige re- vurdering.
The MAH is required to provide updates on the recruitment rates and any intermediary results annually within the annual re- assessment.
MAH skal opdatere status for OS i studie A8081007 og levere de endelige data inden for 9 måneder efter, at det påkrævede antal på 238 events er nået.
The MAH is requested to update OS status of study A8081007 and provide the final data within 9 months after the required 238 OS events have been reached.
MAH skal sikre at uddannelsesprogrammet, der er udarbejdet for de godkendte indikationer  behandling af osteoporose hos postmenopausale kvinder og mænd med øget risiko for knoglebrud, inklusive personer med en nylig lavenergi-hoftefraktur og behandling af osteoporose i forbindelse med længerevarende systemisk glukokortikoidbehandling hos postmenopausale kvinder og mænd med øget risiko for fraktur  opdateres.
The MAH shall ensure that the educational programme implemented for the authorised indications of treatment of osteoporosis in post-menopausal women and in men at increased risk of fracture, including those with a recent low-trauma hip fracture, and treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture is updated.
MAH skal sikre, at alle sundhedspersoner, der forventes at ordinere eller bruge Provenge, får udleveret følgende:
The MAH shall ensure that all healthcare professionals who are expected to prescribe or use Provenge are provided with the following items:
MAH skal, efter drøftelser og efter aftale med den relevante nationale myndighed i de enkelte medlemsstater, hvor OZURDEX markedsføres, ved lanceringen og efter lanceringen sørge for, at alle øjenklinikker, hvor OZURDEX forventes at blive anvendt, får en opdateret lægeinformationspakke med følgende elementer:
The MAH shall ensure that, following discussions and agreement with the National Competent Authorities in each Member State where OZURDEX is marketed, at launch and after launch all ophthalmological clinics where OZURDEX is expected to be used are provided with an updated physician information pack containing the following elements:
MAH vil fortsætte med at indsende årlige PSUR’er, medmindre andet specificeres af CHMP.
The MAH will continue to submit yearly PSURs unless otherwise specified by the CHMP.
MAH vil fremsende resultaterne af en prospektiv kohortesikkerhedsundersøgelse med mindst 9.000 patienter i forskellige aldersgrupper, inklusive immunkompromitterede forsøgspersoner, i henhold til protokollen indsendt med planen for risikostyring.
The MAH will submit the results of a prospective cohort safety study in at least 9,000 patients in different age groups, including immunocompromised subjects, in accordance with the protocol submitted with the Risk Management Plan.
MAH vil fremsende resultaterne af GBS-
The MAH will submit the results of the GBS surveillance study.
MaHR (95% KI)
MaHR (95% CI)
Maintainence of Wakefulness Test (MWT)) og opmærksomhed (f.eks.
Maintenance of Wakefulness Test (MWT)) and attention (e.g.
maj 2015.
2015.
Major + CRNM
Major + CRNM
Major blødning blev defineret ved hjælp af blødningsskalaen i ACUITY.
Major bleeding was defined using the ACUITY bleeding scale.
Major blødning forekom hyppigst på sheath-punkturstedet.
Major bleeding occurred most frequently at the sheath puncture site.
Major blødning opstod hyppigst ved punkturstedet.
Major bleeding occurred most frequently at the sheath puncture site.
Major blødning på ethvert sted, inkl. rapporter med letal udgang
Major haemorrhage at any site including reports with fatal outcome
Major blødning2
Major bleeding2
Major depression (moderat til svær depression).
Treatment of major depressive episodes.
Major depression (moderat til svær depression):
Major depressive disorder
Major Fatal/Life-threatening Bleed: Klinisk åbenbar med en reduktion på >50 g/l af hæmoglobin eller ≥4 infunderede erytrocytenheder; eller fatal; eller intrakraniel; eller intraperikardiel med hjertetamponade; eller med hypovolæmisk shock eller svær hypotension, der kræver pressorstoffer eller operation.
Major Fatal/Life-threatening Bleed: Clinically apparent with >50 g/l decrease in haemoglobin or ≥4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolaemic shock or severe hypotension requiring pressors or surgery.
Major molekulært respons
Major molecular response
Major molekulært respons hos patienter, der opnår CCyRd (%) (95% CI)
Imatinib-resistant patients 44% (35–53) Major molecular response in patients achieving CCyRd (%) (95% CI)
Major Other: Klinisk åbenbar med en reduktion på 30-50 g/l af hæmoglobin eller 2-3 infunderede erytrocytenheder eller svært invaliderende.
Major Other: Clinically apparent with 30 50 g/L decrease in haemoglobin or 2-3 red cell units transfused; or significantly disabling.
Major respons n (%)
Major response n (%)
Major respons ved 84 måneder (%)
Major response at 84 months (%)
majssirup (højt fructoseindhold), propylenglycol (15.3% w/v), renset vand,
propylene glycol (15.3% w/v), purified water,
Majsstivelse Flormelis
Magnesium stearate Maize starch Confectioner’s sugar
Majsstivelse Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat Mikrokrystallinsk cellulose
Maize starch Hydroxypropylcellulose Lactose monohydrate Magnesium stearate Microcrystalline cellulose
Majsstivelse Hydroxypropylcellulose Laktosemonohydrat Magnesiumstearat Mikrokrystallinsk cellulose Indigocarmin aluminium lake
Maize starch Hydroxypropylcellulose Lactose monohydrate Magnesium stearate Microcrystalline cellulose Indigo carmine aluminium lake
Majsstivelse Lactose Povidon
Maize starch Lactose Povidone
Majsstivelse Magnesiumstearat Jernoxid, rød (E172)
Maize starch Magnesium stearate Iron oxide, red (E172)
Majsstivelse Prægelatineret majsstivelse Crospovidon Type A Magnesiumstearat
Maize starch, pregelatinised Crospovidone type A Magnesium stearate
MAKEDSFØRINGSTILLADELSENS NUMMER (NUMRE)
EU/2/96/001/005 EU/2/96/001/008
MAKEDSFØRINGSTILLADELSENS NUMMER (NUMRE)
NUMBERS IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS
Makrocytose blev ikke evalueret ved disse studier, men blev fundet værende forbundet med Zerit i en tidligere afprøvning (MCV > 112 fl forekom hos 30% af patienterne behandlet med Zerit).
Macrocytosis was not evaluated in these trials, but was found to be associated with Zerit in an earlier trial (MCV > 112 fl occurred in 30% of patients treated with Zerit).
Makrofag-aktiveringssyndrom (MAS) er en alvorlig livstruende sygdom, som sJIA-patienter kan udvikle.
Macrophage activation syndrome (MAS) is a serious life-threatening disorder that may develop in sJIA patients.
Makrofag-aktiveringssyndrom (MAS) er en kendt, livstruende tilstand, der kan udvikles hos patienter med reumatiske lidelser, specielt Stills sygdom.
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with rheumatic conditions, in particular Still’s disease.
Makrofag-aktiveringssyndrom hos patienter med Stills sygdom
Macrophage activation syndrome in patients with Still’s Disease
makrogol 300 carbomer renset vand natriumhydroxid (E524) dinatriumedetat butylhydroxyanisol (E320)
macrogol 300 carbomer purified water sodium hydroxide (E524) disodium edetate butylhydroxyanisole (E320)
Makrolidantibiotika
Macrolide antibiotics
makrolider (f.eks. erythromycin, clarithromycin)
macrolides (e.g. erythromycin, clarithromycin)
Makrolider betragtes i reglen som bakteriestatiske og mykoplasmatiske.
Macrolides are generally considered bacteriostatic and mycoplasmastatic.
Makrolider er metabolitter eller derivater af metabolitter fra jordbakterier fremstillet ved fermentering.
Macrolides are metabolites or derivatives of metabolites of soil organisms obtained by fermentation.
makrolider som clarithromycin (antibiotika)
macrolides e.g. clarithromycin (medicine to treat bacterial infections)
Makrolider(f.eks. erythromycin, clarithromycin).
macrolides (e.g. erythromycin, clarithromycin),
makrolider, f.eks. clarithromycin (antibiotika)
macrolides e.g. clarithromycin (medicine to treat bacterial infections)
Makroskopisk hæmaturi/uretral blødning
Macroscopic haematuria/urethral haemorrhage
maks.)
P<0.0001
Maksimal absolut stigning i hepatisk fedtprocent
Maximum Absolute Increase in % Hepatic Fat
Maksimal anbefalet behandlingsperiode er 8 uger.
The maximum recommended treatment duration is 8 weeks.
Maksimal bronkodilatation opnåedes inden for 1-3 timer efter dosering med gennemsnitlige peak forbedringer i FEV1 ift. baseline på 227-268 ml ved steady-state.
Maximal bronchodilation was achieved within 1-3 hours after dosing with mean peak improvements in FEV1 relative to baseline of 227-268 mL at steady-state.
Maksimal daglig dosis
Dosing schedule
Maksimal daglig dosis for Victrelis er 2.400 mg.
Maximum daily dose of Victrelis is 2,400 mg.
Maksimal dosis (mg/døgn)
Maximum dose
Maksimal dosis:
Maximum dose:
maksimal dosis: 12 tabletter dagligt i opdelte doser sammen med eller umiddelbart efter dagens måltider
maximum dose: 12 tablets daily, in separated doses, with or immediately after meals of the day.
Maksimal eksponering (Cmax) på omkring 50 gange større end efter inhalation af glycopyrronum 44 mikrogram ved steady state blev opnået og medførte ikke takykardi eller QTc- forlængelse.
Peak exposures (Cmax) about 50-fold higher than after inhalation of glycopyrronium 44 micrograms at steady state were achieved and did not result in tachycardia or QTc prolongation.
Maksimal gennemsnitlig stigning i serumprolaktinkoncentrationen blev generelt observeret på dag 15 i behandlingen, men koncentrationen forblev over udgangsniveauet ved studiets afslutning.
Maximum mean increases of serum prolactin concentrations were generally observed on Day 15 of treatment, but remained above baseline levels at study endpoint.
Maksimal hæmning af den samtidigt indgivne proteasehæmmers metabolisme opnås generelt med doser af ritonavir på mellem 100 mg daglig og 200 mg to gange daglig og afhænger af den samtidigt indgivne proteasehæmmer.
Maximal inhibition of metabolism of the co-administered protease inhibitor is generally achieved with ritonavir doses of 100 mg daily to 200 mg twice daily, and is dependent on the co-administered protease inhibitor.
Maksimal induktion med CYP3A4/5- induktorer er set indenfor 1 uges behandling med induktoren.
Maximal induction with high-dose strong CYP3A4/5 inducers has been reported to occur within one week of treatment with the inducer.
Maksimal infusionshastighed
Maximum infusion rate
Maksimal inspiratorisk flow igennem Spiromax-devicet
Peak Inspiratory Flow Rate through theSpiromax Device
Maksimal inspiratorisk flowhastighed gennem Spiromax-inhalationsdevice
Peak Inspiratory Flow Rate through the Spiromax Device
Maksimal koncentration opnås gennemsnitligt på halvdelen af tiden for opløseligt humaninsulin.
The time to maximum concentration is, on average, half of that for soluble human insulin.
Maksimal milbemycinoxim plasmakoncentrationer nås hurtigt inden for de første 1–2 timer (Tmax), hvilket indikerer at absorptionen fra tyggetabletten er hurtig.
Milbemycin oxime plasma concentrations peak quickly within the first 1–2 hours (Tmax) indicating that absorption from the chewable is fast.
Maksimal plasmakoncentration (Cmax) af eslicarbazepin opnås 2 til 3 timer efter administration, og steady state-plasmakoncentration opnås efter 4 til 5 dages daglig indgift, svarende til en effektiv halveringstid på 20 til 24 timer.
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 2-3 hours post-dose and steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 h.
Maksimal plasmakoncentration (Cmax) af eslicarbazepin opnås 2 til 3 timer efter administration, og steady state-plasmakoncentration opnås efter 4 til 5 dages daglig indgift, svarende til en effektiv halveringstid på 20 til 24 timer.
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 2-3 hours post-dose and steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 hours.
Maksimal plasmakoncentration af den absorberede del af fipronil og (S)-methopren nås i løbet af 8-9 timer.
The peak plasma concentrations of the absorbed fraction of fipronil and (S)-methoprene are reached in 8 to 9 hours.
Maksimal plasmakoncentration efter en enkelt dosis telaprevir opnås generelt efter 4-5 timer.
Maximum plasma concentrations after a single dose of telaprevir are generally achieved after 4 – 5 hours.
Maksimal plasmakoncentration efter infusion (IE/dl)
Maximum Plasma Concentration Post Infusion (IU/dl)
Maksimal plasmakoncentration for det hurtigtvirkende insulin opnås 1,5-2,5 timer efter subkutan indgivelsesmåde.
The maximum plasma concentration of the fast-acting insulin is reached within 1.5–2.5 hours after subcutaneous administration.